Compound repurposing
Small molecule compounds are being studied for repurposing in COVID-19 treament and research. Multiple small molecules that are approved to treat other disorders have shown potential effects on key proteins involved in SARS-CoV-2 host cell entry and replication. Repurposing of existing compounds is advantageous for speed - reducing timescales compared to conventional drug discovery. Researchers can save up to 50% on these small molecules for COVID-19 research, as they are up to half the price of other suppliers.
AICAR (HB2152)
Description:AMPK activator. Promotes osteogenic differentiation of bone marrow-derived MSCs.
Purity:>99%
- Description:
Immunostimulant. Natural killer T cell stimulator.
Purity:>96%
(±)-Anatoxin A fumarate (HB2023)
Description:Potent nicotinic agonist. Apoptosis inducer.
Purity:>99%
Aniracetam (HB0116)
Description:Nootrophic AMPA receptor positive allosteric modulator
Purity:>98%
Anisomycin (HB2239)
Description:Protein synthesis inhibitor. Potent JNK / p38 MAPK activator.
Purity:>98%
L-AP4 (HB0370)
Description:L-AP4 is a selective group III mGluR agonist which inhibits synaptic transmission.
Purity:>99%